131 related articles for article (PubMed ID: 37595597)
21. Impact of body mass index on surgical outcomes and analysis of disease recurrence for patients with endometrial cancer undergoing robotic-assisted staging.
Menderes G; Azodi M; Clark L; Xu X; Lu L; Ratner E; Schwartz PE; Rutherford TJ; Santin AD; Silasi DA
Int J Gynecol Cancer; 2014 Jul; 24(6):1118-25. PubMed ID: 24927247
[TBL] [Abstract][Full Text] [Related]
22. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
[TBL] [Abstract][Full Text] [Related]
23. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
[TBL] [Abstract][Full Text] [Related]
24. Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort.
Farrell R; Dixon SC; Carter J; Webb PM
Int J Gynecol Cancer; 2017 Sep; 27(7):1379-1386. PubMed ID: 30814240
[TBL] [Abstract][Full Text] [Related]
25. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy.
Narayan K; Khaw P; Bernshaw D; Mileshkin L; Kondalsamy-Chennakesavan S
Int J Gynecol Cancer; 2012 Feb; 22(2):260-6. PubMed ID: 22080878
[TBL] [Abstract][Full Text] [Related]
27. High-grade endometrial carcinoma limited to the endometrium or a polyp: is adjuvant treatment necessary?
Dallaire Nantel L; Renaud MC; Gregoire J; Sebastianelli A; Plante M
Int J Gynecol Cancer; 2021 Oct; 31(10):1335-1340. PubMed ID: 34518241
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
29. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
[TBL] [Abstract][Full Text] [Related]
30. Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.
Elshaikh MA; Vance S; Suri JS; Mahan M; Munkarah A
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):351-6. PubMed ID: 24411608
[TBL] [Abstract][Full Text] [Related]
31. Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
Shinde A; Li R; Amini A; Chen YJ; Cristea M; Dellinger T; Wang W; Wakabayashi M; Beriwal S; Glaser S
Gynecol Oncol; 2018 Oct; 151(1):82-90. PubMed ID: 30170976
[TBL] [Abstract][Full Text] [Related]
32. Bone metastases in endometrial cancer: report on 19 patients and review of the medical literature.
Uccella S; Morris JM; Bakkum-Gamez JN; Keeney GL; Podratz KC; Mariani A
Gynecol Oncol; 2013 Sep; 130(3):474-82. PubMed ID: 23685013
[TBL] [Abstract][Full Text] [Related]
33. Pure compared with mixed serous endometrial carcinoma: two different entities?
Roelofsen T; van Ham MA; Wiersma van Tilburg JM; Zomer SF; Bol M; Massuger LF; Bulten J
Obstet Gynecol; 2012 Dec; 120(6):1371-81. PubMed ID: 23168762
[TBL] [Abstract][Full Text] [Related]
34. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
[TBL] [Abstract][Full Text] [Related]
35. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.
Martinez AA; Weiner S; Podratz K; Armin AR; Stromberg JS; Stanhope R; Sherman A; Schray M; Brabbins DA
Gynecol Oncol; 2003 Sep; 90(3):537-46. PubMed ID: 13678721
[TBL] [Abstract][Full Text] [Related]
36. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
37. Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
Ko EM; Brensinger CM; Cory L; Giuntoli RL; Haggerty AF; Latif NA; Aviles D; Martin L; Morgan MA; Lin LL
Gynecol Oncol; 2020 Nov; 159(2):394-401. PubMed ID: 32800655
[TBL] [Abstract][Full Text] [Related]
38. Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid Carcinoma.
Miyamoto M; Tsuda H; Sugiura A; Kita T; Kataoka Y; Ishii K; Kudo K; Matsuura H; Ishibashi H; Iwahashi H; Hada T; Suzuki R; Takano M
In Vivo; 2021; 35(2):1205-1209. PubMed ID: 33622922
[TBL] [Abstract][Full Text] [Related]
39. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.
Zhang Z; Wang J; Wu X; Liu Y; Xi X
J Obstet Gynaecol Res; 2022 Aug; 48(8):2180-2188. PubMed ID: 35778826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
